{"id":2071,"date":"2019-04-15T15:38:59","date_gmt":"2019-04-15T15:38:59","guid":{"rendered":"https:\/\/rhepa.se\/?p=2071"},"modified":"2021-05-12T08:20:33","modified_gmt":"2021-05-12T08:20:33","slug":"rhenman-partners-wins-prestigious-award-at-the-nordic-hedge-awards-best-performance-awards-for-5-years","status":"publish","type":"post","link":"https:\/\/rhepa.se\/en\/rhenman-partners-wins-prestigious-award-at-the-nordic-hedge-awards-best-performance-awards-for-5-years\/","title":{"rendered":"Rhenman & Partners wins prestigious award at the Nordic Hedge Awards: Best Performance Awards for 5 Years"},"content":{"rendered":"
Since inception in June 2009, the fund has had annualised returns of +19%
\nThe sector fund Rhenman Healthcare Equity L\/S was named a winner at this year\u2019s Nordic
\nHedge Awards; best-performing Nordic hedge fund for five years. The award was made in
\nthe category “Performance Award for 60 Months”.
\n“We are tremendously pleased over this award. The Nordic Hedge Award is the most prestigious
\nNordic award for hedge funds and a total of 172 funds were evaluated in 2018. To put it simply,
\nthis is the Nordic championship and to win the category for the longest time period is a testament to
\nour unique investment process which leads the way, even internationally,” says Carl Grevelius, cofounder and head of investor relations.
\n“Our success depends largely on the many years of close collaboration between our fund managers
\nand the medical experts in our Scientific Advisory Board. Equally important is our investment team’s
\nsingle focus on the healthcare sector which includes pharmaceuticals, biotechnology, medical
\ntechnology and service. This sectoral focus probably gives us a knowledge advantage compared to
\nthose investors who monitor and invest in a number of sectors.\u201d
\nRhenman Healthcare Equity L\/S has an unprecedented performance history since its inception in
\nJune 2009. The main fund class, the IC1 (EUR), has increased by 449 percent in total, which
\ncorresponds to an average annual net return of 19 percent. In the first quarter 2019, the fund
\ndelivered a return of more than 15 percent. At present, assets under management in
\nthe fund exceed 600 million EUR.
\nFor further information, please contact:
\nCarl Grevelius, Founding Partner \/ Head of Investor Relations
\nPhone: +46 8 459 88 83
\nEmail: carl@rhepa.com
\nwww.rhepa.com<\/p>\n
About Rhenman & Partners
\nRhenman & Partners Asset Management, founded in 2008, is a Stockholm-based asset manager
\nfocusing on two niche funds: Rhenman Healthcare Equity L\/S, launched in June 2009,
\nand Rhenman Global Opportunities L\/S, launched in August 2016. Assets under
\nmanagement exceed 600 MEUR. The management teams of the two funds are supported in their
\nrespective investment processes by renowned advisors consisting of, among others,
\neminent professors and experts with many years of market experience and extensive expert
\nnetworks around the world<\/p>\n","protected":false},"excerpt":{"rendered":"
Since inception in June 2009, the fund has had annualised returns of +19% The sector fund Rhenman Healthcare Equity L\/S was named a winner at this year\u2019s Nordic Hedge Awards; best-performing Nordic hedge fund for five years. The award was made in the category “Performance Award for 60 Months”. “We are tremendously pleased over this […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false},"categories":[15],"tags":[],"aioseo_notices":[],"yoast_head":"\n